IMUX — IMMUNIC, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1280776 ·
Last close
$7.33
Market Cap
$100.01M
52W High
$17.43
52W Low
$5.06
ADV30
300,713
Next earnings
2026-11-13
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -43,369,000 -42,309,000 136,423,000 131,963,000 31,950,000
Jun 2026 0 — -35,327,000 -34,099,000 159,169,000 155,098,000 31,588,000
Mar 2026 0 — -33,235,000 -32,588,000 189,742,000 186,629,000 38,509,000
Dec 2025 0 — -23,327,000 -19,300,000 24,052,000 15,483,000 30,725,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-87,720,000
Investing CF
$-329,000
Financing CF
$65,577,000
CapEx
$-329,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.18
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-675,258,000
Inventory
—
Receivables
$281,000
ST Investments
—
EBIT TTM
$-117,882,000
Pretax Income TTM
$-111,566,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -103,228,000 -97,172,000 24,052,000 30,725,000 -6,673,000 -85,806,000
Dec 2024 0 -98,052,000 -100,507,000 40,868,000 22,439,000 18,429,000 -84,766,000
Dec 2023 0 -99,223,000 -93,612,000 54,299,000 25,368,000 28,931,000 -70,828,000
Dec 2022 0 -86,518,000 -120,407,000 127,753,000 14,069,000 113,684,000 -65,144,000

TTM Snapshot

Revenues TTM
$2,662,000
NetIncome TTM
$-111,566,000
OpCashFlow TTM
—
Assets (Latest)
$159,169,000
Forward EPS
$-2.37

Max Pain — expiry 2027-01-15

max pain strike: $7.50 · spot: $7.52 · call oi: 1,384 · put oi: 733
Expected Move to 2027-01-15: ±$4.10 (54.52%) — implied range $3.42 – $11.62 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EQ Equillium, Inc. $99.61M $1.21 —
ADAG Adagene Inc. $99.37M $1.48 —
HSTC HST Global, Inc. $99.00M $0.70 —
UNCY Unicycive Therapeutics, Inc. $101.35M $3.70 —
OGI ORGANIGRAM GLOBAL INC. $101.90M $0.71 —

News headlines (Yahoo Finance, 1h cache)

Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
2026-11-13 14:10 · Yahoo
Why Is Immunic Stock Falling 5% Following Its Third-Quarter Results?
2026-11-13 13:47 · Yahoo
Immunic shares fall 5% on third quarter earnings miss
2026-11-13 12:14 · Yahoo
MARKETS LIVE: Wall Street ends volatile week mixed as Nvidia selloff weighs on tech stocks
2026-11-13 11:56 · Yahoo
Immunic: Q3 Earnings Snapshot
2026-11-13 11:36 · Yahoo
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 11:30 · Yahoo
Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts
2026-11-12 15:26 · Yahoo
Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
2026-11-06 05:14 · Yahoo
Immunic to Participate in Investor Conferences in November
2026-11-02 11:30 · Yahoo
Immunic highlights progressive MS research and Phase 3 outlook at MSToronto2026
2026-10-30 17:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.